Videos

Fred Saad, MD, FRCS, University of Montreal, discusses the benefit of radium-223 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Hendrik-Tobias Arkenau, MD, PhD, executive medical director, Drug Development Unit, Sarah Cannon Research Institute-United Kingdom, discusses the future of immunotherapy in melanoma.

David J. Stewart, MD, head, Division of Medical Oncology, University of Ottawa/The Ottawa Hospital, discusses a study that investigated the impact of delaying approval on overall survival.

Christoph Roellig, MD, University Hospital Dresden, Dresden, Germany, discusses FLT3 ITD/NPM1 mutation status for patients with AML who are in first remission.

Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with relapse/refractory acute myeloid leukemia (AML).

Aziz Nazha, MD, discusses a new mutational model to predict response to hypomethylating agents in myelodysplastic syndromes (MDS).

Srdan Verstovsek, MD, PhD, the University of Texas MD Anderson Cancer Center, discusses immunotherapy in myelofibrosis.

Jennifer R. Brown, MD, PhD, Dana-Farber Cancer Institute, discusses new drugs on the horizon for the treatment of patients with chronic lymphocytic leukemia (CLL).

Joshua M. Bauml, MD, assistant professor, University of Pennsylvania, discusses the significant impacts of a new electronic platform.

Scott Eggener, MD, associate professor of surgery, co-director, Prostate Cancer Program, director, Transitional and Outcomes Research, Section of Urology, The University of Chicago Medicine, discusses racial disparities in men with prostate cancer.

Lecia V. Sequist, MD, MPH, associate professor of medicine, Massachusetts General Hospital, discusses the IMPRESS trial, which was presented at the 2015 World Conference on Lung Cancer.

Daniel S. Oh, MD, assistant professor of surgery, University of Southern California, Keck School of Medicine, discusses myPlan genetic testing in patients with lung cancer.

Stacy Loeb, MD, assistant professor, Urology and Population Health, NYU Langone Medical Center, discusses the controversy of screening and treatment in men with prostate cancer, as well as data from the National Prostate Cancer Register (NPCR) of Sweden.

Lajos Pusztai, MD, PhD, Yale Cancer Center, discusses DNA abnormalities in breast cancer.

Anees B. Chagpar, MD, MPH, MBA, Yale Comprehensive Cancer Center, discusses contralateral prophylactic mastectomy for patients with breast cancer.

Alok Khorana, MD, discusses the long-term impacts of tinzaparin versus warfarin, as well as clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients, in the CATCH study.

Jeffrey N. Weitzel, MD, director, Clinical Cancer Genetics, director, Cancer Screening & Prevention Program Network, professor, City of Hope, discusses the impact of gene mutations on treatment.

James Kearns, MD, discusses genetic correction of prostate-specific antigen (PSA) and how it can reduce the number of patients diagnosed with potentially insignificant prostate cancer

Fred C. Kass, MD, oncology/hematology, internal medicine, Cancer Center of Santa Barbara, discusses HER2-positive breast cancer advancements.

Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses the impact of immunotherapy in prostate cancer.

Melvin J. Silverstein, MD, FACS, Hoag Memorial Hospital Presbyterian, discusses the benefits of oncoplastic surgery for patients with breast cancer.

Matthew H. Taylor, MD, Oregon Health and Science University, discusses the toxicities and impact of lenvatinib in the SELECT trial, which treated patients with 131I-refractory differentiated thyroid cancer.

Anthony D. Elias, MD, professor, Division of Medical Oncology, University of Colorado Denver, discusses the future of androgen receptors in breast cancer.

Marcia S. Brose, MD, PhD, discusses the SELECT trial, which looks at lenvatinib for patients with 131I-refractory differentiated thyroid cancer.

Bishoy M. Faltas, MD, Fellow, Hematology/Oncology, Weill Cornell Medical College, discusses immunotherapy in platinum-resistant bladder cancer.